Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO
This is a multi-centre, open-label, descriptive pharmacokinetic (PK) study.
VentiLatIon management oF patients with Extracorporeal membrane oxyGenation for Acute Respiratory Distress Syndrome
LIFEGARDS is a multicenter, observational study assessing the mechanical ventilation management of patients with ARDS undergoing ECMO, in a worldwide population over a one-year period.
HEparin Low-dose Protocol in ECMO Patients
HELP ECMO is a single center, randomized, controlled feasibility study assessing the use of low-dose heparin, as compared with full-dose heparin, in critically ill patients undergoing ECMO. This study is closed.
ECMO to rescue Lung Injury in severe ARDS
EOLIA is a multicenter, international, randomized, controlled trial run by the REVA network and endorsed by the International ECMO Network. The study hypothesizes that ECMO, instituted early after the diagnosis of very severe ARDS (P:F < 80), would lower the morbidity and mortality associated with this syndrome. This study is closed.
PRotective vEntilation with veno-venouS lung assisT in respiratory failure
Randomized, allocation concealed, controlled, open, phase 3 pragmatic clinical effectiveness trial to determine whether VV-ECCO2R in mechanically ventilated patients with acute hypoxaemic respiratory failure in intensive care improves mortality at 90 days.
Strategies for Optimal Lung Ventilation in ECMO for ARDS
To assess if a CPAP strategy that minimizes end-tidal pulmonary stress/strain mitigates VILI in comparison to current MV using tidal ventilation in severe ARDS patients on VV ECMO.
A Strategy of UltraProtective lung ventilation With Extracorporeal CO2 Removal for New-Onset moderate to seVere ARDS
SUPERNOVA is an ESICM-sponsored trial which has been endorsed by the International ECMO Network. This study assessed changes in pH / PaO2 /PaCO2, Respiratory Rate and device CO2 clearance in the first 24 hours of ECCO2R following VT and plateau pressure reduction in patients with moderate ARDS. Safety variables during treatment will also be analyzed. This study is closed.
ImmunoDeficiency and ECMO for Acute respiratory failure
This study will provide, for the first time, detailed descriptive data on the characteristics, the complication and the outcome of adult’s immunocompromised patients receiving ECMO for ARDS. This study is closed
Gas eXchange eXtracorporeaL techniques: How many candidates in the ICU?
Prospective, observational study screening patients that meet criteria for ECLS to evaluate the incidence of patients who may be candidates for the different forms of extracorporeal support in ICU.
ECMO PT is a multicentre, randomised, trial of whether early individualised physical training (commenced within first 48 hours of ECMO) is feasible and improves functional recovery (the highest level of activity and duration) compared to standard care in ECMO patients.